Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GALT 
Galectin Therapeutics Inc (GALT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/14/2025: GALT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.18% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 356.57M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 0.95 | 52 Weeks Range 0.73 - 6.55 | Updated Date 11/15/2025 |
52 Weeks Range 0.73 - 6.55 | Updated Date 11/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
Earnings Date
Report Date 2025-11-17 | When - | Estimate -0.18 | Actual -0.13 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -98.3% | Return on Equity (TTM) -3727.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 464232447 | Price to Sales(TTM) - |
Enterprise Value 464232447 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.04 | Shares Outstanding 64479210 | Shares Floating 45088815 |
Shares Outstanding 64479210 | Shares Floating 45088815 | ||
Percent Insiders 30.07 | Percent Institutions 16.03 |
Upturn AI SWOT
Galectin Therapeutics Inc
Company Overview
History and Background
Galectin Therapeutics, Inc. was founded in 2000. It is a biotechnology company focused on developing therapies for fibrotic and inflammatory diseases, particularly NASH.
Core Business Areas
- Drug Development: Focuses on the development of novel therapies targeting galectin proteins to treat fibrosis and cancer.
- NASH Treatment: Developing a specific galectin-3 inhibitor, belapectin, for the treatment of Non-alcoholic steatohepatitis (NASH) with cirrhosis.
Leadership and Structure
The leadership team includes individuals with experience in biotechnology and drug development. The organizational structure is typical of a small biotech company, with departments focused on research, development, and clinical trials.
Top Products and Market Share
Key Offerings
- Belapectin: Belapectin is the company's lead drug candidate, a galectin-3 inhibitor in development for the treatment of NASH cirrhosis. Market share is currently 0% as it is not yet approved but future revenue depend on approval. Competitors include Madrigal Pharmaceuticals(MDGL), Viking Therapeutics (VKTX).
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on NASH treatment is competitive and growing. Many companies are developing drugs to target different aspects of the disease.
Positioning
Galectin Therapeutics is positioned as a company focusing on galectin-3 inhibition as a novel approach to treating NASH cirrhosis. This offers a unique mechanism compared to other NASH therapies.
Total Addressable Market (TAM)
The NASH market is expected to reach billions of dollars. Galectin Therapeutics is positioned to capture a portion of this market if belapectin is approved, as NASH represents a large unmet need.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (galectin-3 inhibition)
- Potential first-in-class therapy for NASH cirrhosis
- Experienced management team
- Orphan drug designation for belapectin
Weaknesses
- Single product pipeline
- High dependence on clinical trial success
- Limited financial resources compared to larger competitors
- No currently approved products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into other fibrotic diseases
- Positive clinical trial results
- Fast track or breakthrough therapy designation
Threats
- Clinical trial failures
- Competition from other NASH therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MDGL
- GILD
- VKTX
- AKRO
Competitive Landscape
Galectin Therapeutics' competitive advantage lies in its novel approach to treating NASH cirrhosis with a galectin-3 inhibitor. However, larger companies with more resources pose a competitive threat.
Growth Trajectory and Initiatives
Historical Growth: Galectin Therapeutics' historical growth has been primarily focused on advancing belapectin through clinical trials.
Future Projections: Future projections depend on the success of clinical trials and potential regulatory approvals. Analyst estimates may vary based on these factors.
Recent Initiatives: Recent initiatives include enrollment in the Phase 3 trial for belapectin in NASH cirrhosis and exploring potential partnerships.
Summary
Galectin Therapeutics is a biotech company with a focus on developing belapectin for NASH cirrhosis. The company's success hinges on the outcome of its Phase 3 trial. Though it has a novel approach, it faces competition from companies with deeper pockets. Clinical trial results and regulatory approvals are key to its future growth and is dependent on raising more capital.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galectin Therapeutics Inc
Exchange NASDAQ | Headquaters Norcross, GA, United States | ||
IPO Launch date 2002-09-09 | President, CEO & Director Mr. Joel Lewis CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://galectintherapeutics.com |
Full time employees 15 | Website https://galectintherapeutics.com | ||
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.